(CercleFinance.com) – Ipsen announces the signing of an exclusive global licensing agreement with Sutro Biopharma for STRO-003, an antibody-small molecule conjugate (ADC) currently entering its final stages of preclinical development.
This ADC candidate, the first to join Ipsen’s expanding portfolio, targets the tumor antigen ROR1, known to be overexpressed in many types of cancer, including hematologic malignancies and solid tumors.
‘STRO-003 demonstrated effectiveness as a monotherapy and displayed a satisfactory safety profile during its preclinical development in solid tumors and hematological malignancies’, underlines the pharmaceutical laboratory.
Under the agreed terms, Ipsen obtains exclusive global development and commercialization rights, and Sutro Biopharma is eligible for payments of up to $900 million.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
